Healthlinx Limited
Healthlinx Limited (ASX: HTX) is an emerging biomarker and diagnostic company with an integrated platform in biomarker and bioactive peptide discovery platforms. The company develops novel, non-invasive, serum-based, diagnostic products. The Ovarian Cancer Program has completed a phase II biomarker trial with the outcome being the development of the first generation ovarian cancer diagnostic, OvPlex™.
HealthLinx Ltd launches ovarian cancer test into UK market
HealthLinx (ASX: HTX) has reported that UK distribution partner Intus Healthcare is targeting a significant share of the potential 750,000 annual ovarian cancer diagnostic tests undertaken in the UK with the product launch of OvPlex™ on 25 February 2010.
The company obtained European Certification for OvPlex™ paving the way to market and sell the product within the European community.
Nick Gatsios, managing director of HealthLinx said the UK launch will be the first large scale roll out of OvPlex™ and HealthLinx will receive a royalty of approximately $70 per test.
The UK marketing launch of OvPlex™ on such a large scale will build a platform for HealthLinx to target other countries.
The company has opened discussions in Korea, China, other European countries for OvPlex™ and has been approached by some Central South American countries, providing strong commercial upside opportunities.
The recent announcement that OvPlex™ was awarded BioSpectrum Product of the Year in Asia Pacific for 2010 by an independent jury chaired by Dr G Steven Burrill of Burrill and Co, further supports the commercial opportunity for the product.
Each year 240,000 new cases of ovarian cancer are diagnosed worldwide and over 130,000 women die from the disease. The UK region accounts for over 7,000 of these diagnoses and 4,000 lives lost per year.
Other Healthlinx Limited articles
Other Healthlinx Limited news
-
08/06/10 HealthLinx raises A$750,000 through private placement
-
17/02/10 HealthLinx Limited secures samples for ovarian cancer study
-
12/01/10 Healthlinx looking to become market leader with ovarian cancer diagnostic, OvPlex™
-
02/12/09 HealthLinx opens up key UK market for its OvPlex™ Ovarian Cancer Diagnostic
-
11/09/09 HealthLinx's ovarian diagnostic test takes aim at industry leader









